Author

Nampueng Churikanont

Observed institution: Armed Forces Research Institute of Medical Science

OpenAlex ID: A5083172737

Safety and efficacy of VRC01 broadly neutralising antibodies in adults with acutely treated HIV (RV397): a phase 2, randomised, double-blind, placebo-controlled trial

2019 · Trevor A Crowell, Donn J Colby, et al. · The Lancet HIV · 106

Extended Evaluation of the Virologic, Immunologic, and Clinical Course of Volunteers Who Acquired HIV-1 Infection in a Phase III Vaccine Trial of ALVAC-HIV and AIDSVAX B/E

2012 · Supachai Rerks-Ngarm, Robert M. Paris, et al. · The Journal of Infectious Diseases · 58

Late boosting of the RV144 regimen with AIDSVAX B/E and ALVAC-HIV in HIV-uninfected Thai volunteers: a double-blind, randomised controlled trial

2020 · Punnee Pitisuttithum, Sorachai Nitayaphan, et al. · The Lancet HIV · 46

Long-term antiretroviral therapy initiated in acute HIV infection prevents residual dysfunction of HIV-specific CD8+ T cells

2022 · Hiroshi Takata, Juyeon C. Kakazu, et al. · EBioMedicine · 39

Impact of Acute HIV Infection and Early Antiretroviral Therapy on the Human Gut Microbiome

2019 · Ornella Sortino, Nittaya Phanuphak, et al. · Open Forum Infectious Diseases · 36

Vaccine Induced Seroreactivity Following Administration of ALVAC-HIV/AIDSVAX®B/E Identified by Common Anti-HIV Test Kits and Algorithms in Thailand

2025 · Siriwat Akapirat, Elisavet Serti, et al. · Open Forum Infectious Diseases · 1

Impact of Early Antiretroviral Treatment on Tissue-Resident Memory CD4+ T Cells in the Gastrointestinal Tract

2026 · Sinmanus Vimonpatranon, Aloysious Ssemaganda, et al. · The Journal of Infectious Diseases

Works count: 7

Citation count: 286

H-index: 5

I10-index: 5